TGF-β Promotes CD103+ TRM Cell Differentiation via Smad-Independent TRAF6 Activation of the Transcriptional Runx3-β-Catenin-TCF1-ID3-Eomes and Metabolic TAK1-AMPK-ULK1-ATG7 Pathways
Year: 2026
Type: preprint
Abstract: Background. CD103+ tissue-resident memory T (TRM)-cells reside in peripheral and lymphoid tissues, rapidly respond to antigen re-encounter and are emerging as an important player in immunity against infection and cancers. Transforming-growth factor-beta (TGF-β) is known to regulate TRM-cell differentiation; however, the underlying mechanism remains unclear. Methods. In this study, we employed an established cell-culture protocol that uses TGF-β to induce CD8+ T-cell differentiation into TRM-cells. We systematically characterized these TRM-cells by flow cytometry, Western blotting, electron and confocal microcopy, biochemical and metabolic Seahorse assay analyses. Results. We demonstrated that TGF-β promotes the formation of TRM-cells which exhibit prolonged cell survival associated with upregulated expression of TCF1, Bcl2, the effector cytokines TNF-α and IFN-γ and cytolytic granzyme-B when compared to control, IL-2-stimulated effector T (TE)-cells. In addition, the TRM-cells have an increased mitochondrial mass, a higher O2 consumption rate and lower NADH levels and mitochondrial membrane potential, all of which favor fatty acid oxidation (FAO) for ATP production. The TRM-cells also up-regulate the expression of TNF receptor-associated factor-6 (TRAF6) and its downstream substrates in a Smad-independent manner, while down-regulating the expression of the Blimp1 and T-bet transcription factors which are enriched in TE-cells. These downstream TRAF6 substrates include the transcription factors Runx3 (controlling CD103 expression), β-catenin, TCF1, ID3 and Eomes and autophagic/metabolic regulators TAK1, AMPK, ULK1, ATG7, OPA1, PGC-1α and Complex I, which are collectively necessary for the transition to the TRM-cell phenotype and increased reliance on FAO metabolism to preserve energy homeostasis. Conclusion. Our novel findings elucidate that TGF-β signaling promotes TRM-cell formation via the Smad-independent regulation of TRAF6, which in turn activates the transcriptional Runx3-β-catenin-TCF1-ID3-Eomes and metabolic TAK1-AMPK-ULK1-ATG7 pathways. Our mechanistic characterization of the associated signaling nodes identifies additional therapeutic candidates, and will thus greatly impact the on-going development of targeted TRM cell-based immunotherapies for cancer and infectious diseases.
Source: Preprints.org
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7226023490
